Article

<i>Enterococcus</i> peptidoglycan remodeling promotes immune checkpoint inhibitor therapy

2020-08-20

Abstract excerpt

The antitumor efficacy of cancer immunotherapy has been correlated with specific species within the gut microbiota. However, molecular mechanisms by which these microbes affect host response to immunotherapy remain elusive. Here we show that specific members of the bacterial genus Enterococcus can promote anti-PD-L1 immunotherapy in mouse tumor models. The active enterococci express and secrete orthologs of the N...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f95270a4-0fd5-5546-93aa-abd16ccc6556
DOI: 10.1101/2020.08.20.256263

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>Enterococcus</i> peptidoglycan remodeling promotes immune checkpoint inhibitor therapyDOI 10.1101/2020.08.20.256263Read

Microbial mechanisms to improve immune checkpoint blockade responsivenessSemantic proximity Read

Gut Microbiota Shifts from Onset to Remission in Immune Checkpoint Inhibitor-Induced Enterocolitis: A Case ReportSemantic proximity Read

The gut microbiome and cancer response to immune checkpoint inhibitorsSemantic proximity Read

<i>N</i> -arylpyrazole NOD2 agonists promote immune checkpoint inhibitor therapySemantic proximity Read

A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapySemantic proximity Read

<i>Listeria monocytogenes</i> personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigensSemantic proximity Read

Human Microbial Transplant Restores T Cell Cytotoxicity and Anti-Tumor Response to PD-L1 Blockade in Gnotobiotic MiceSemantic proximity Read

Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?Semantic proximity Read

Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancerSemantic proximity Read

Unlocking The Potential and Myth of Personalized Vaccines, CRISPR-CAS9, and Bacteriotherapy, as Therapeutic Options for CancerSemantic proximity Read

ACB1801 enhances tumor immunogenicity by targeting glycolysis/ferroptosis vulnerability and activating STAT1-signaling to overcome anti-PD-1 resistance in MSS colorectal cancerSemantic proximity Read

In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapySemantic proximity Read